AZD 5153

Drug Profile

AZD 5153

Alternative Names: AZD5153

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 04 Jul 2017 AstraZeneca plans a phase I trial for Solid tumours and Lymphoma (Metastatic disease, Second-line therapy or greater) in USA (NCT03205176)
  • 30 Jun 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT03205176)
  • 16 Apr 2016 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top